When the initial 114 serum samples were tested by ELISA, serum LRG1 was found to be approximately 2-fold greater in serous ovarian cancer patients' sera compared to sera from healthy control women; however, the variance among the ovarian cancer patient samples resulted in unfavorable estimates of sensitivity and specificity. Here, LRG1 is linked to ovarian carcinoma.